Finding prostate cancer metastates in lymph nodes early

With the help of an engineered common cold virus spreadings of prostate cancer in the pelvic lymph nodes can be visualised with a PET scanner. It is now possible to treat the cancer in an early stage. But the developers of the virus from UCLA's Jonsson Comprehensive Cancer Center see a chance to even use it as a treatment option.

Lily Wu, M.D., Ph.D.
Lily Wu, M.D., Ph.D.
Using an engineered common cold virus, UCLA researchers delivered a genetic payload to prostate cancer cells that allowed them, using positron emission tomography (PET), to locate the diseased cells as they spread to the lymph nodes, the first place prostate cancer goes before invading other organs.
 
The tiny cancer metastases in the pelvic lymph nodes are very difficult to find using conventional imaging tools such as CT scanning. This discovery could aid oncologists in finding the cancer's spread earlier, when it's more treatable and before it invades distant organs, said Lily Wu, a researcher at UCLA's Jonsson Cancer Center and the senior author of the study, which appears July 11 in the early, online edition of the peer-reviewed journal Nature Medicine.
 
The next step for Wu and her colleagues is linking the non-invasive imaging advance with a treatment component, activating a toxic agent in the genetic payload to kill the spreading cancer cells. Wu hopes one day to be able to find tiny prostate cancer metastases in patients and kill them at the same time, watching it all on a PET scanner. She currently is refining this image-guided therapy in her lab in mouse models.
 
"I think this is very exciting for many reasons," said Wu, who also is an associate professor of pharmacology and urology. "We now know we can reach these prostate cancer metastases at an earlier stage than before, and we know we can deliver genes to those cancer cells that produce proteins that can be imaged by PET. Now we will find out how effective this genetic toxic payload is in preventing further spread of the cancer to other vital organs."
 
The spread of prostate cancer to the pelvic lymph nodes is the most reliable indicator that the patient will have a poor prognosis, with disease recurrence and progression likely. Accurately assessing pelvic lymph node involvement in patients is critical in planning their treatment, Wu said.
 
Currently, physicians don't know if a treatment is attacking cancer cells until, using traditional imaging, they see a decrease in tumor size, an insensitive approach that can take weeks and months. And if the treatment isn't working, the patient is exposed to a toxic therapy that isn't helping them. If Wu is successful, an oncologist would know within days if the cancer has spread and whether the treatment is killing the cancer.
 
Using mouse models, Wu and her team engineered a virus to travel to the lymph nodes, using a prostate cancer-specific vector that dictates its protein payload be expressed only in prostate cells. The payload in this case is a protein that can be imaged by PET scanning. The virus was introduced into the tumor in the mouse and Wu and her team were able to detect PET signals only from the lymph nodes with cancer cell involvement, indicating the virus reached and infected the prostate cancer cells and produced the imaging protein.
 
As part of this study, Wu co-developed TSTA, a two-step transcriptional amplification method, which increased the expression of the genetic payload inside the cancer cells — in effect boosting the imaging signals and potential killing activity of the engineered virus.
 
Wu believes this type of image-guided therapy has the potential to improve the way advanced prostate cancer is treated.
 
"It would represent a treatment advance in patients for whom the outcome is not good," Wu said. "This would help improve the prognosis for these patients by letting us find and treat these metastases early. If we can catch the cancer before it invades other organs, we have a better chance to change the outcomes for these patients."
 
This type of approach was pioneered in the field of breast cancer with testing of the sentinel lymph node, the first place breast cancer goes when it spreads. A biopsy can determine if the cancer is in the sentinel node, therefore spreading, and oncologists base their treatment decisions on that information. In prostate cancer, the lymph nodes are much more difficult to access for biopsy, so Wu's method provides a much needed, non-invasive alternative.
 
Wu's work was initiated more than five years ago with the support of an interdisciplinary grant from the Jonsson Cancer Center.
 
For more information, visit www.cancer.ucla.edu.

17.07.2008

More on the subject:
Read all latest stories

Related articles

Photo

News • Nuclear imaging

New PET radiotracer to reduce false-positive cancer findings after Covid-19 vaccination

A novel imaging agent can reduce the number of false-positive PET/CT findings among cancer patients recently vaccinated for Covid-19. This may mitigate the issue of tracer uptake in lymph nodes…

Photo

Article • Image augmentation, interpretation and evaluation

AI in multimodality hybrid imaging: a diamond in the rough

AI-based models for multimodality hybrid imaging have the potential to be a potent clinical tool but are currently held back by a lack of transparency and maturity, says Dr Irène Buvat, from the…

Photo

News • T cell visualization

Whole body scan shows complexity of immunotherapy response

Dutch scientists have performed whole-body PET scans using a radioactively labeled antibody tracer against immune cells, to predict the effect of treatment with immune checkpoint inhibitors.

Related products

Subscribe to Newsletter